Prostate cancer secondary prevention: Difference between revisions
No edit summary |
Sapan Patel (talk | contribs) No edit summary |
||
| Line 2: | Line 2: | ||
{{CMG}} | {{CMG}} | ||
{{Prostate cancer}} | {{Prostate cancer}} | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
| Line 13: | Line 11: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
| Line 21: | Line 16: | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category: | [[Category:Needs content]] | ||
[[Category:Primary care]] | |||
[[Category:Needs overview]] | |||
{{WH}} | |||
{{WS}} | |||
Revision as of 19:54, 16 April 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
|
Prostate cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Prostate cancer secondary prevention On the Web |
|
American Roentgen Ray Society Images of Prostate cancer secondary prevention |
|
Risk calculators and risk factors for Prostate cancer secondary prevention |
Secondary Prevention
Active Surveillance
Active Surveillance refers to observation and regular monitoring without invasive treatment. Active surveillance is often used when an early stage, slow-growing prostate cancer is found in an older man. Conversely watchful waiting may also be suggested when the risks of surgery, radiation therapy, or hormonal therapy outweigh the possible benefits. Other treatments can be started if symptoms develop, or if there are signs that the cancer growth is accelerating (e.g., rapidly rising PSA, increase in Gleason score on repeat biopsy, etc.). Most men who choose active surveillance for early stage tumors eventually have signs of tumor progression, and they may need to begin treatment within three years.[1] Although men who choose active surveillance avoid the risks of surgery and radiation, the risk of metastasis (spread of the cancer) may be increased.
For younger men, a trial of active surveillance may not mean avoiding treatment altogether, but may reasonably allow a delay of a few years or more, during which time the quality of life impact of active treatment can be avoided. Published data to date suggest that carefully selected men will not miss a window for cure with this approach. Additional health problems that develop with advancing age during the observation period can also make it harder to undergo surgery and radiation therapy.